Watch the September 28 conference call for final transaction details, including any disclosed deal value, expected revenue contributions from YUPELRI and TRELEGY, and any updated financial guidance. The integration of Theravance's commercial assets could meaningfully shift Zymeworks' revenue profile.
Price Chart
Executive Summary
Zymeworks completed its acquisition of Theravance Biopharma, adding YUPELRI and TRELEGY royalty streams to its portfolio. The deal advances Zymeworks' strategy of building a diversified, revenue-generating biotech with commercial assets and a pipeline of novel biotherapeutics.
Key Facts
- Zymeworks completed the acquisition of Theravance Biopharma, making Theravance part of Zymeworks.
- The acquisition adds YUPELRI (revefenacin) and TRELEGY royalty interests to Zymeworks' portfolio.
- Zymeworks will host a conference call on September 28, 2026 to discuss final transaction details.
- The deal is part of Zymeworks' strategy to build a diversified revenue-generating biotechnology company with commercial and royalty-based cash flows.
Financial Impact
Acquisition adds commercial assets (YUPELRI) and royalty streams (TRELEGY) to Zymeworks; deal value not disclosed in the press release.
Risk Factors
- Integration risks and potential failure to realize anticipated synergies from the acquisition.
- Commercial performance of YUPELRI and TRELEGY may fall short of expectations.
- Pipeline candidates may fail in development or face regulatory delays.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3367828 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | DEFA14A | $28.23 | awaiting T+1 | — | $28.95 (+2.55%) |
Oct 26, 2026 today | DEF 14A | $28.37 | awaiting T+1 | — | $28.95 (+2.04%) |
Oct 23, 2026 4d ago | 8-K | $28.22 $28.37 | ▲ +0.53% | ▼ −0.18% | $28.95 (+2.59%) |
Oct 15, 2026 12d ago | Press Release | $25.75 $25.03 | ▼ −2.80% | ▼ −1.69% | $28.95 (+12.43%) |
Oct 9, 2026 18d ago | 144 | $25.79 $25.33 | ▼ −1.78% | ▼ −1.72% | $28.95 (+12.25%) |
Sep 28, 2026 29d ago | Press Release | $27.12 $27.20 | ▲ +0.29% | ▲ +0.48% | $28.95 (+6.75%) |
Sep 23, 2026 4w ago | Press Release | $26.81 $26.52 | ▼ −1.08% | ▼ −1.63% | $28.95 (+7.98%) |
Aug 25, 2026 9w ago | 8-K | $27.47 $29.31 | ▲ +6.68% | ▲ +6.66% | $28.95 (+5.39%) |
Jul 16, 2026 14w ago | Press Release | $24.19 | awaiting T+1 | — | $28.95 (+19.68%) |
Jun 29, 2026 17w ago | Press Release | $24.10 $26.14 | ▲ +8.46% | ▲ +7.69% | $28.95 (+20.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers